
FDA Approves Pertuzumab Biosimilar for HER2-Positive Breast Cancer
Key Takeaways
- Indications mirror reference pertuzumab: metastatic first-line with trastuzumab plus docetaxel, and early-stage neoadjuvant/adjuvant use with trastuzumab and chemotherapy for higher-risk disease.
- Commercial availability is not immediate; a patent settlement establishes the earliest licensed US launch in Q3 2028, delaying any potential payer-driven cost or access effects.
The pertuzumab biosimilar is set to be commercially available in the third quarter of 2028.
The FDA approved pertuzumab-qcay (Pebrilzo; Biocon), a biosimilar to pertuzumab (Perjeta; Genentech), as a treatment for adults with HER2-positive breast cancer in metastatic and early-stage settings, according to an announcement on November 16th, 2026, from Biocon.¹
This approval contributes another HER2-directed biologic option, although commercial availability will follow a separate timeline. Under a global patent settlement and license agreement with Genentech announced in October, Biocon secured an earliest licensed US launch date in the third quarter of 2028.²
For pharmacists, the announcement provides an opportunity to prepare for a future pertuzumab biosimilar while reinforcing the monitoring requirements associated with HER2-directed treatment. The approval itself does not establish immediate availability or a specific reduction in patients’ treatment costs.¹˒²
Indications Span Metastatic and Early Breast Cancer
In the metastatic setting, pertuzumab-qcay is indicated with trastuzumab (Herceptin; Genentech) and docetaxel for adults with HER2-positive disease who have not received previous anti-HER2 therapy or chemotherapy for metastatic breast cancer.¹
For early breast cancer, the biosimilar is indicated with trastuzumab and chemotherapy as neoadjuvant treatment for adults with HER2-positive, locally advanced, inflammatory, or early-stage disease that is greater than 2 cm in diameter or node positive. Treatment is administered as part of a complete regimen for early breast cancer. The approval also includes adjuvant use with trastuzumab and chemotherapy for adults with HER2-positive early breast cancer at high risk of recurrence.¹
These indications position the biosimilar within combination treatment regimens. Its role depends on the disease setting and the accompanying agents, making accurate regimen verification an important consideration when the product becomes available.¹
Approval Supported by Biosimilarity Evidence
According to Biocon, the approval was supported by structural and functional analytical characterization, analytical similarity assessments, and comparative clinical pharmacokinetic data. The company reported that the evidence demonstrated high similarity to the reference product without clinically meaningful differences in quality, safety, efficacy, or immunogenicity.¹
The FDA’s biosimilar framework evaluates whether a proposed product is highly similar to its reference biologic and has no clinically meaningful differences in safety, purity, or potency. This pathway generally avoids the need to repeat the full clinical development program used to establish the reference product’s efficacy.³
That distinction matters when explaining the approval to patients. Biosimilarity supports an expectation of the same treatment benefits and risks as the reference biologic; it does not represent evidence that the new product improves cancer outcomes over pertuzumab.³
Cardiac and Infusion Monitoring Remain Central
Pertuzumab-qcay carries boxed warnings for left ventricular dysfunction and embryo-fetal toxicity. Cardiac function should be evaluated before treatment and monitored during therapy because pertuzumab can cause decreased left ventricular ejection fraction and clinical heart failure. The safety information calls for discontinuation for a confirmed clinically significant decline in left ventricular function.¹
Patients should also receive counseling about fetal harm and effective contraception. Additional warnings include infusion-related reactions and hypersensitivity reactions, including anaphylaxis. The company’s safety information recommends close observation for 60 minutes after the first infusion and 30 minutes after subsequent infusions.¹
For context, the reference product’s prescribing information specifies an initial 840-mg intravenous infusion over 60 minutes, followed every 3 weeks with 420 mg over 30 to 60 minutes.⁴
In the metastatic regimen with trastuzumab and docetaxel, adverse reactions reported in more than 30% of patients include diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy. These events reflect the combination regimen and should inform supportive care and patient counseling.¹
US Launch Will Follow the Approval
The settlement establishes a future market-entry timeline rather than an immediate change in treatment access. As launch approaches, pharmacy teams can evaluate formulary placement and payer coverage while preparing product-specific ordering and patient education materials.
The FDA notes that biosimilar competition can potentially lower health care costs. For pertuzumab-qcay, the practical effect on access will become clearer as commercial availability and coverage details emerge.²˒³
REFERENCES
Biocon gets U.S. FDA approval for Pebrilzo (pertuzumab-qcay) injection, a biosimilar to Perjeta, expanding its oncology portfolio. News release. Biocon. November 16, 2026. Accessed November 16, 2026.
https://www.businesswire.com/news/home/20261116435734/en/Biocon-Gets-U.S.-FDA-Approval-for-Pebrilzo-pertuzumab-qcay-Injection-a-Biosimilar-to-Perjeta-Expanding-Its-Oncology-Portfolio Biocon secures earliest licensed launch dates for Pebrilzo (bPertuzumab) following global patent settlement with Genentech. Biocon. October 14, 2026. Accessed November 16, 2026.
https://www.biocon.com/biocon-secures-earliest-licensed-launch-dates-for-pebrilzo-bpertuzumab-following-global-patent-settlement-with-genentech/https://www.biocon.com/biocon-secures-earliest-licensed-launch-dates-for-pebrilzo-bpertuzumab-following-global-patent-settlement-with-genentech/ Overview for health care professionals. FDA. Accessed November 16, 2026.
https://www.fda.gov/drugs/biosimilars/overview-health-care-professionals Perjeta. Prescribing information. Genentech; April 2026. Accessed November 16, 2026.
https://www.gene.com/download/pdf/perjeta_prescribing.pdf
Related to this article








